Literature DB >> 9676821

Polymorphisms in the dopamine, serotonin, and norepinephrine transporter genes and their relationships to monoamine metabolite concentrations in CSF of healthy volunteers.

E G Jönsson1, M M Nöthen, J P Gustavsson, H Neidt, R Bunzel, P Propping, G C Sedvall.   

Abstract

Concentrations of monoamine metabolites (MM) in lumbar cerebrospinal fluid (CSF) have been used extensively as indirect estimates of monoamine turnover in the brain. We investigated the possible relationships between DNA polymorphisms in the dopamine transporter (DAT), serotonin transporter (SERT), and norepinephrine transporter (NET) genes and CSF concentrations of homovanillic acid (HVA), 5-hydroxyindoleacetic acid (5-HIAA), and 3-methoxy-4-hydroxyphenylglycol (MHPG) in healthy volunteers (n = 66). The DAT polymorphism was not significantly associated with any of the monoamine metabolites, but a tendency for relationship with 5-HIAA was found in women. For both of the two SERT polymorphisms investigated, a functional promoter polymorphism and an intronic polymorphism without known function, significant relationships were found with CSF MHPG levels. No relationship was found between the SERT polymorphisms and CSF HVA and 5-HIAA. The NET polymorphism was associated with CSF MHPG levels but not HVA and 5-HIAA concentrations. The results suggest that SERT and NET genotypes may participate differentially in the regulation of the norepinephrine turnover rate under presumed steady-state conditions in the central nervous system. As only limited data so far indicate interactions between the serotonin and norepinephrine systems in the brain, and the NET polymorphism investigated is not known to be of functional significance, the results should be interpreted with caution until replicated.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9676821     DOI: 10.1016/s0165-1781(98)00027-4

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  21 in total

1.  Assessing the cost-effectiveness of pharmacogenomics.

Authors:  D L Veenstra; M K Higashi; K A Phillips
Journal:  AAPS PharmSci       Date:  2000

Review 2.  Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine.

Authors:  Colin N Haile; Thomas R Kosten; Therese A Kosten
Journal:  Am J Drug Alcohol Abuse       Date:  2009       Impact factor: 3.829

Review 3.  Genetic Influence on Efficacy of Pharmacotherapy for Pediatric Attention-Deficit/Hyperactivity Disorder: Overview and Current Status of Research.

Authors:  Nada A Elsayed; Kaila M Yamamoto; Tanya E Froehlich
Journal:  CNS Drugs       Date:  2020-04       Impact factor: 5.749

Review 4.  Neuroimaging genomic studies in major depressive disorder: A systematic review.

Authors:  Hui-Feng Zhang; David Mellor; Dai-Hui Peng
Journal:  CNS Neurosci Ther       Date:  2018-02-23       Impact factor: 5.243

Review 5.  Looking Beyond the 5-HTTLPR Polymorphism: Genetic and Epigenetic Layers of Regulation Affecting the Serotonin Transporter Gene Expression.

Authors:  Sandra Iurescia; Davide Seripa; Monica Rinaldi
Journal:  Mol Neurobiol       Date:  2016-12-08       Impact factor: 5.590

6.  Lack of association between the norepinephrine transporter gene and major depression in a Han Chinese population.

Authors:  Chuan-Chia Chang; Ru-Band Lu; Chih-Lun Chen; Chi-Ming Chu; Hsin-An Chang; Cheng-Chang Huang; Yi-Lin Huang; San-Yuan Huang
Journal:  J Psychiatry Neurosci       Date:  2007-03       Impact factor: 6.186

7.  A quantitative trait locus for variation in dopamine metabolism mapped in a primate model using reference sequences from related species.

Authors:  Nelson B Freimer; Susan K Service; Roel A Ophoff; Anna J Jasinska; Kevin McKee; Amelie Villeneuve; Alexandre Belisle; Julia N Bailey; Sherry E Breidenthal; Matthew J Jorgensen; J John Mann; Rita M Cantor; Ken Dewar; Lynn A Fairbanks
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-20       Impact factor: 11.205

8.  Monoamine transporter gene polymorphisms affect susceptibility to depression and predict antidepressant response.

Authors:  Wenjiao Min; Tao Li; Xiaohong Ma; Zhengyu Li; Tao Yu; Dong Gao; Bo Zhang; Yang Yun; Xueli Sun
Journal:  Psychopharmacology (Berl)       Date:  2009-05-26       Impact factor: 4.530

9.  Relationship of genetic variability and depressive symptoms to adverse events after coronary artery bypass graft surgery.

Authors:  Barbara Phillips-Bute; Joseph P Mathew; James A Blumenthal; Richard W Morris; Mihai V Podgoreanu; Michael Smith; Mark Stafford-Smith; Hilary P Grocott; Debra A Schwinn; Mark F Newman
Journal:  Psychosom Med       Date:  2008-11       Impact factor: 4.312

10.  Influence of serotonergic/noradrenergic gene polymorphisms on nausea and sweating induced by milnacipran in the treatment of depression.

Authors:  Hisashi Higuchi; Hitoshi Takahashi; Mitsuhiro Kamata; Keizo Yoshida
Journal:  Neuropsychiatr Dis Treat       Date:  2009       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.